ASLAN PHARMACEU/ADR (NASDAQ:ASLN) and Melinta Therapeutics (NASDAQ:MLNT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.
This table compares ASLAN PHARMACEU/ADR and Melinta Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
7.2% of ASLAN PHARMACEU/ADR shares are owned by institutional investors. Comparatively, 19.5% of Melinta Therapeutics shares are owned by institutional investors. 60.3% of Melinta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares ASLAN PHARMACEU/ADR and Melinta Therapeutics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|ASLAN PHARMACEU/ADR||$11.55 million||4.44||-$42.19 million||($1.40)||-1.14|
|Melinta Therapeutics||$96.43 million||0.42||-$157.19 million||($17.72)||-0.17|
ASLAN PHARMACEU/ADR has higher earnings, but lower revenue than Melinta Therapeutics. ASLAN PHARMACEU/ADR is trading at a lower price-to-earnings ratio than Melinta Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
ASLAN PHARMACEU/ADR has a beta of 2.4, indicating that its share price is 140% more volatile than the S&P 500. Comparatively, Melinta Therapeutics has a beta of 4.54, indicating that its share price is 354% more volatile than the S&P 500.
This is a summary of recent ratings for ASLAN PHARMACEU/ADR and Melinta Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ASLAN PHARMACEU/ADR presently has a consensus price target of $8.00, suggesting a potential upside of 400.00%. Melinta Therapeutics has a consensus price target of $25.75, suggesting a potential upside of 769.93%. Given Melinta Therapeutics’ higher possible upside, analysts clearly believe Melinta Therapeutics is more favorable than ASLAN PHARMACEU/ADR.
Melinta Therapeutics beats ASLAN PHARMACEU/ADR on 8 of the 13 factors compared between the two stocks.
ASLAN PHARMACEU/ADR Company Profile
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4. Its Varlitinib is currently being studied in a global pivotal clinical trial for biliary tract cancer. It is also conducting a Phase II/III clinical trial of varlitinib for gastric cancer; and testing in a single-arm pivotal clinical trial in biliary tract cancer in China. In addition, the company is developing ASLAN003, an orally active potent inhibitor of human dihydroorotate dehydrogenase that is in Phase II clinical trials to treat acute myeloid leukemia; and ASLAN004, an interleukin 4/interleukin 13 receptor antibody for the treatment of severe atopic dermatitis and asthma. It has rights to develop, manufacture, and commercialize varlitnib for all human and animal therapeutic, diagnostic, and prophylactic uses. ASLAN Pharmaceuticals Limited has partnerships with Array BioPharma, Bristol-Myers Squibb, Almirall, and CSL Limited. ASLAN Pharmaceuticals Limited was founded in 2010 and is headquartered in Singapore.
Melinta Therapeutics Company Profile
Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is headquartered in New Haven, Connecticut.
Receive News & Ratings for ASLAN PHARMACEU/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEU/ADR and related companies with MarketBeat.com's FREE daily email newsletter.